A Randomized, Open-Label Phase II/III Multicenter Study of High Dose Immunosuppressive therapy

Medicine and Dentistry

1. Therapeutic Procedure 100%
2. Mortality 100%
3. Organ 100%
4. Drug Megadose 100%
5. Immunosuppressive Treatment 100%
6. Skin 75%
7. Scleroderma 75%
8. Cyclophosphamide 75%
9. Event Free Survival 75%
10. Dermatosis 50%
11. Diseases 50%
12. Combination Therapy 50%
13. Disease-Modifying Antirheumatic Drug 50%
14. Transplantation 50%
15. Immune Reconstitution 50%
16. Assessment 50%
17. Health Assessment 25%
18. Gastrointestinal Disease 25%
19. Short Form 36 25%
20. Death 25%
21. Consent 25%
22. Outpatient 25%
23. Physician 25%
24. Renal Failure 25%
25. Systemic Scleroderma 25%
26. Toxicity 25%
27. Infectious Complication 25%
28. Lung Function 25%
29. Myositis 25%
30. Prognosis 25%
31. Hospital Inpatient 25%
32. Gender 25%
33. Engraftment 25%
34. Quality of Life 25%
35. Age 25%
36. Population Research 25%
37. Survival 25%
38. Stem Cell Therapy 25%